Vanguard Group Inc
- SEC CIK
- 0000102909
- Latest filing
- Jan 29, 2026
SEEL holding history
Seelos Therapeutics, Inc. in every 13F filed by Vanguard Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SEEL overviewAll 13F holders of SEELFull Q4 2025 holdings
- Shares (Q2 2024)
- 0
- Sold out in Q2 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 13
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2024 | 0 | $0 | 0.0% | −280,866−100.0% | Sold out | Holders |
| Q1 2024 | 280,866 | $166.0K | <0.1% | −3,012−1.1% | Reduced | Holders |
| Q4 2023 | 283,878 | $394.6K | <0.1% | +111,454+64.6% | AddedConverted for a 1-for-30 split | Holders |
| Q3 2023 | 5,172,726 | $951.8K | <0.1% | +175,078+3.5% | Added | Holders |
| Q2 2023 | 4,997,648 | $5.97M | <0.1% | −19,093−0.4% | Reduced | Holders |
| Q1 2023 | 5,016,741 | $3.47M | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 5,016,741 | $3.41M | <0.1% | +2,4010.0% | Added | Holders |
| Q3 2022 | 5,014,340 | $5.16M | <0.1% | +86,990+1.8% | Added | Holders |
| Q2 2022 | 4,927,350 | $3.35M | <0.1% | −723,638−12.8% | Reduced | Holders |
| Q1 2022 | 5,650,988 | $4.74M | <0.1% | +504,505+9.8% | Added | Holders |
| Q4 2021 | 5,146,483 | $8.39M | <0.1% | −31,020−0.6% | Reduced | Holders |
| Q3 2021 | 5,177,503 | $12.5M | <0.1% | +377,180+7.9% | Added | Holders |
| Q2 2021 | 4,800,323 | $12.7M | <0.1% | +1,879,159+64.3% | Added | Holders |
| Q1 2021 | 2,921,164 | $14.6M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.